Bloomberg -- Drugmakers desperate for innovative medicines are courting a tiny French company whose lab holds a product that may transform the treatment of heart attacks. Cerenis Therapeutics SA, a closely held company, is testing a compound in a new class of drugs that mimic high-density lipoprotein, also known as good cholesterol, to purge arteries clogged by plaque.
